Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to...
Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to...
In this free webinar, learn how the recent policy and regulatory shifts are influencing vaccine access. Attendees will examine changes...
Los Angeles, California--(Newsfile Corp. - August 28, 2025) - In a powerful act of unity and determination, five mothers—each having...
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and...
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: Revenue surged 404% year over year to...
In this free webinar, gain insight into rapid, reliable analytics for evolving mRNA modalities. Attendees will learn about mRNA modality-specific CQA...
Physicians, researchers, and partner institutions across Europe aim to deliver innovative, personalized therapies more quickly Development project focused on a...
ALEXANDRIA, Va., Aug. 26, 2025 /PRNewswire/ -- BryceTech has secured three multi-year prime contracts from the U.S. Department of Defense,...
ALEXANDRIA, Va., Aug. 26, 2025 /PRNewswire/ -- BryceTech has secured three multi-year prime contracts from the U.S. Department of Defense,...
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire...
NEW CASTLE, Del., Aug. 21, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, is proud to announce...
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following...
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has...
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...
SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy...
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive...
AI Virtual Agents Powering Operational Gains for 135+ Healthcare Providers Through 1,000+ Distinct Flows SANTA BARBARA, Calif., Aug. 14, 2025...